Abstract:Background: While reporting of adverse drug events (AE) and adverse drug reactions (ADR) following Chinese materia medica (CM) injection is becoming more common, the reporting quality is of concern. Methods: A checklist about the reporting quality of AE/ADR was set up, and the ADR/AE reporting of Herba Houttuyniae injection was chosen as an example. Electronic databases Chinese Journal Net (1994-2009) and Chinese Science and Technological Journal Net (VIP) (1989-2009) were searched for target literature. Results: Based on our search strategy, 210 articles were included, with 175 articles reporting single or several cases of ADR/AE following Herba Houttuyniae injection (type I report). There were seven reports from regional or national ADR monitoring centers (type II report), and 28 summary reports from a single hospital or medical center (type III report). All 210 papers mentioned "adverse effect,""safety" or related meaning words in their titles, but 199 articles did not have abstract. Patient demographic characteristics were not fully reported in these articles. In type I articles, only 97 cases (43.11%) mentioned whether patients had or did not have a history of allergies, whereas 128 cases (56.89%) in type II papers and 14 (50%) type III papers, did not mention allergic history of patients. Only three articles (3/210, 1.43%), all of them type I, mentioned the syndrome type in Chinese medicine. None of the papers gave clear indications of the type and grade of ADR/AE of patients. Most papers did not report details of the CM injection procedure, such as the drug company, product serial number, or the drug's validity period. Data about the occurrence time and management of ADR/AE was also inadequately reported. Conclusion and recommendations: The current reporting format of ADR/AE in clinical CM injections is not standardized. Much fundamental information of ADR/AE following CM injection is therefore missing. A standard reporting format for ADR should be developed, and should include the following: (1) a title mentioning adverse effects and safety; (2) a structured abstract including adequate information about the patient and the disease treated, the drug used, the specific ADR/AE, physician response to the ADR/AE, and result of management; (3) demographic characteristic of the patients (gender, age, etc.); (4) clinical characteristics of patients (disease, syndrome, etc); (5) allergic history of patients; (6) diagnosis and syndrome based on Chinese medicine theory; (7) detailed information about the CM intervention (the manufacturer of the drug, series number, valid dates, dosage, route of administration, menstruum, dripping speed, etc.); (8) concomitant drug use; (9) time and symptoms of ADR/AE; (10) type and grading of ADR/AE; (11) physiological systems affected by ADR/AE; (12) specific treatment and prognosis for ADR/AE; (13) evidence of the cause and effect of ADR/AE; and (14) any other possibility of ADR/AE. Also, a ADR/AE registration system should be established.

Analysis of 3123 Reports on Suspected Medical Device Adverse Event

[Analysis on Evaluation of Medical Device Adverse Events Monitoring and Some Factors Influencing MDAE's Reporting by Medical Personnels].

Medical device report analyses from MAUDE: Device and patient outcomes, adverse events, and sex-based differential effects

The Survey of Healthcare Professionals on Awareness for Medical Device Administration Events Monitoring

Analysis of a Pharmacist-Led Adverse Drug Event Management Model for Pharmacovigilance in an Academic Medical Center Hospital in China

Comparative Study on Monitoring System of Medical Device Adverse Events in America, European Union and China

Retrospective Analysis of ADR Cases Reported in 2006 in Shenzhen

Analysis on 522 cases of antibacterial-related adverse drug reaction/event reports

Analysis on 342 Repors and Discssion about the Methods of Prevention with Adverse Drug Reactions/events

An evaluation of the Manufacturer And User Facility Device Experience database that inspired the United States Food and Drug Administration's Reclassification of transvaginal mesh

Quality Analysis of the Adverse Drug Reactions Reports from Shanghai Healthcare Professionals

Analysis on 115 Cases of ADR Reports in Our Hospital

Analysis of the Adverse Drug Reactions Reports of 139 Cases

Research on Evaluation Method for MDRs'quality

Incidence and related factors of administration events in intermediate frequency electrical therapy

The severity of adverse drug reactions and their influencing factors based on the ADR monitoring center of Henan Province

Analysis on 428 Cases Adverse Drug Reaction/event Reports of Antibacterial Agents

Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica

Analysis of 408 Total Ankle Arthroplasty Adverse Events Reported to the US Food and Drug Administration from 2015 to 2018

Trend Analysis of Inpatient Medical Adverse Events in Taiwan (2014–2020)—Findings From Taiwan Patient Safety Reporting System

2008-2011 Adverse Drug Reaction Analysis of 490 Cases in Huadong Hospital